159 related articles for article (PubMed ID: 26863200)
1. Hydrosulfide Adducts of Organo-Iridium Anticancer Complexes.
Štarha P; Habtemariam A; Romero-Canelón I; Clarkson GJ; Sadler PJ
Inorg Chem; 2016 Mar; 55(5):2324-31. PubMed ID: 26863200
[TBL] [Abstract][Full Text] [Related]
2. Novel and Versatile Imine-N-Heterocyclic Carbene Half-Sandwich Iridium(III) Complexes as Lysosome-Targeted Anticancer Agents.
Yang Y; Guo L; Tian Z; Gong Y; Zheng H; Zhang S; Xu Z; Ge X; Liu Z
Inorg Chem; 2018 Sep; 57(17):11087-11098. PubMed ID: 30133276
[TBL] [Abstract][Full Text] [Related]
3. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
[TBL] [Abstract][Full Text] [Related]
4. Novel half-sandwich iridium(iii) imino-pyridyl complexes showing remarkable in vitro anticancer activity.
Li J; Guo L; Tian Z; Tian M; Zhang S; Xu K; Qian Y; Liu Z
Dalton Trans; 2017 Nov; 46(44):15520-15534. PubMed ID: 29090698
[TBL] [Abstract][Full Text] [Related]
5. Activation of the Ir-N(pyridine) Bond in Half-Sandwich Tethered Iridium(III) Complexes.
Carrasco AC; Rodríguez-Fanjul V; Pizarro AM
Inorg Chem; 2020 Nov; 59(22):16454-16466. PubMed ID: 33103884
[TBL] [Abstract][Full Text] [Related]
6. Contrasting reactivity and cancer cell cytotoxicity of isoelectronic organometallic iridium(III) complexes.
Liu Z; Salassa L; Habtemariam A; Pizarro AM; Clarkson GJ; Sadler PJ
Inorg Chem; 2011 Jun; 50(12):5777-83. PubMed ID: 21618978
[TBL] [Abstract][Full Text] [Related]
7. Similarities and differences in d
Gilewska A; Barszcz B; Masternak J; Kazimierczuk K; Sitkowski J; Wietrzyk J; Turlej E
J Biol Inorg Chem; 2019 Jun; 24(4):591-606. PubMed ID: 31115765
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of cellular accumulation of an iridium(III) pentamethylcyclopentadienyl anticancer complex containing a C,N-chelating ligand.
Novohradsky V; Liu Z; Vojtiskova M; Sadler PJ; Brabec V; Kasparkova J
Metallomics; 2014 Mar; 6(3):682-90. PubMed ID: 24448555
[TBL] [Abstract][Full Text] [Related]
9. Novel iridium(III) iminopyridine complexes: synthetic, catalytic, and in vitro anticancer activity studies.
Kong D; Tian M; Guo L; Liu X; Zhang S; Song Y; Meng X; Wu S; Zhang L; Liu Z
J Biol Inorg Chem; 2018 Jul; 23(5):819-832. PubMed ID: 29934699
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships for highly potent half-sandwich organoiridium(III) anticancer complexes with C^N-chelated ligands.
Yang Y; Guo L; Ge X; Shi S; Gong Y; Xu Z; Zheng X; Liu Z
J Inorg Biochem; 2019 Feb; 191():1-7. PubMed ID: 30445339
[TBL] [Abstract][Full Text] [Related]
11. Half-sandwich rhodium(III) transfer hydrogenation catalysts: Reduction of NAD(+) and pyruvate, and antiproliferative activity.
Soldevila-Barreda JJ; Habtemariam A; Romero-Canelón I; Sadler PJ
J Inorg Biochem; 2015 Dec; 153():322-333. PubMed ID: 26601938
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, molecular structure, computational study and in vitro anticancer activity of dinuclear thiolato-bridged pentamethylcyclopentadienyl Rh(III) and Ir(III) complexes.
Gupta G; Garci A; Murray BS; Dyson PJ; Fabre G; Trouillas P; Giannini F; Furrer J; Süss-Fink G; Therrien B
Dalton Trans; 2013 Nov; 42(43):15457-63. PubMed ID: 24022745
[TBL] [Abstract][Full Text] [Related]
13. Organometallic Iridium(III) anticancer complexes with new mechanisms of action: NCI-60 screening, mitochondrial targeting, and apoptosis.
Hearn JM; Romero-Canelón I; Qamar B; Liu Z; Hands-Portman I; Sadler PJ
ACS Chem Biol; 2013; 8(6):1335-43. PubMed ID: 23618382
[TBL] [Abstract][Full Text] [Related]
14. Effect of cysteine thiols on the catalytic and anticancer activity of Ru(II) sulfonyl-ethylenediamine complexes.
Chen F; Romero-Canelón I; Habtemariam A; Song JI; Banerjee S; Clarkson GJ; Song L; Prokes I; Sadler PJ
Dalton Trans; 2022 Mar; 51(11):4447-4457. PubMed ID: 35226015
[TBL] [Abstract][Full Text] [Related]
15. Alkyl chain-modified cyclometalated iridium complexes as tunable anticancer and imaging agents.
Laha P; De U; Chandra F; Dehury N; Khullar S; Kim HS; Patra S
Dalton Trans; 2018 Nov; 47(44):15873-15881. PubMed ID: 30358775
[TBL] [Abstract][Full Text] [Related]
16. Anticancer potential of (pentamethylcyclopentadienyl)chloridoiridium(III) complexes bearing κP and κP,κS-coordinated Ph2 PCH2 CH2 CH2 S(O)x Ph (x=0-2) ligands.
Ludwig G; Ranđelović I; Maksimović-Ivanić D; Mijatović S; Bulatović MZ; Miljković D; Korb M; Lang H; Steinborn D; Kaluđerović GN
ChemMedChem; 2014 Jul; 9(7):1586-93. PubMed ID: 24470190
[TBL] [Abstract][Full Text] [Related]
17. Contrasting Anticancer Activity of Half-Sandwich Iridium(III) Complexes Bearing Functionally Diverse 2-Phenylpyridine Ligands.
Millett AJ; Habtemariam A; Romero-Canelón I; Clarkson GJ; Sadler PJ
Organometallics; 2015 Jun; 34(11):2683-2694. PubMed ID: 26146437
[TBL] [Abstract][Full Text] [Related]
18. Organometallic half-sandwich iridium anticancer complexes.
Liu Z; Habtemariam A; Pizarro AM; Fletcher SA; Kisova A; Vrana O; Salassa L; Bruijnincx PC; Clarkson GJ; Brabec V; Sadler PJ
J Med Chem; 2011 Apr; 54(8):3011-26. PubMed ID: 21443199
[TBL] [Abstract][Full Text] [Related]
19. DFT Investigation of the Mechanism of Action of Organoiridium(III) Complexes As Anticancer Agents.
Ritacco I; Russo N; Sicilia E
Inorg Chem; 2015 Nov; 54(22):10801-10. PubMed ID: 26492153
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, physicochemical characterization and antiproliferative activity of phosphino Ru(II) and Ir(III) complexes.
Komarnicka UK; Kozieł S; Skórska-Stania A; Kyzioł A; Tisato F
Dalton Trans; 2022 Jun; 51(22):8605-8617. PubMed ID: 35615959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
